Asthma market to remain stable over next decade, despite generic erosion

Newly-released research shows that the market for asthma treatment will remain stable, increasing slightly from $15.1 billion in 2013 to $16.1 billion in 2023 in the USA, France, Germany, Italy, Spain, the UK and Japan.

According to Decision Resources Group’s report, as the current market leaders, which includes GlaxoSmithKline’s (LSE: GSK) Advair/Seretide/Adoair (fluticasone propionate and salmeterol), AstraZeneca’s (LSE: AZN) Symbicort (budesonide and formoterol) and Merck & Co (NYSE: MRK)/Kyorin’s Singulair (montelukast) undergo generic erosion, asthma sales in later years will be driven by uptake of novel therapies.

Upcoming therapies

These novel therapies include the once-daily long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination GlaxoSmithKline/Theravance’s (Nasdaq: THRX) Breo/Relvar (fluticasone furoate/vilanterol), Boehringer Ingelheim/Pfizer’s (NYSE: PFE) Spiriva (tiotropium bromide; the first LAMA approved for the treatment of asthma), and five novel anticytokine agents - GSK’s Bosatria(mepolizumab), Teva’s (NYSE: TEVA) Cinquil(reslizumab), AstraZeneca/Kyowa Hakko Kirin’s benralizumab, Roche (ROG: SIX)/Chugai’s lebrikizumab, and AstraZeneca’s tralokinumab.

Other key findings from the Pharmacor report, titled Asthma, include: